May 19, 2020 / 7:06 AM / 19 days ago

BRIEF-Carbiotix Streamlines Clinical Study Plan

May 19 (Reuters) - Carbiotix AB (publ):

* CARBIOTIX STREAMLINES CLINICAL STUDY PLAN TO REDUCE RISK AND REACH PROFITABILITY SOONER

* TO POSTPONE PLANNED PRE-CLINICAL AND CLINICAL STUDIES FOR CANDIDATES IBD (CBX111) AND HYPERAMMONEMIA (CBX121)

* LAUNCH IS ESTIMATED TO H2 2021 IN US TO THEN INITIATE CLINICAL TRIALS DURING H1 2022 REGARDING IBD (CBX111) AND HYPERAMMONEMIA (CBX121) TO REACH A BRAND NEW MARKET FOR ITS PREBIOTIC PRODUCTS FOR GASTRIC HEALTH

* DECIDED NOT TO DO ANIMAL STUDIES IN PRECLINICAL DEVELOPMENT Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below